|
|
Vaccine Detail
|
SRL172 |
| Vaccine Information |
- Vaccine Name: SRL172
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004610
- Type: Live, attenuated vaccine
- Status: Research
- IL12
gene engineering:
- Immunization Route: Intramuscular injection (i.m.)
- Description: This trial provides preliminary evidence of a new, non-toxic, immunotherapeutic regimen in the management of malignant melanoma (Nicholson et al., 2003).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: no responses were seen in the first 16 patients receiving SRL172 alone (Nicholson et al., 2003)
|
| References |
Nicholson et al., 2003: Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma research. 2003; 13(4); 389-393. [PubMed: 12883365].
|
|
